Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Celltrion, Inc.
  6. News
  7. Summary
    A068270   KR7068270008


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Celltrion Receives CHMP Positive Opinion for regdanvimab (CT-P59) as One of the First Monoclonal Antibodies for COVID-19 by the CHMP

11/15/2021 | 10:09am EST

INCHEON, Korea - Celltrion Group announced that the European Medicine's Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive scientific opinion recommending marketing authorisation for regdanvimab (CT-P59), a monoclonal antibody treatment for adults with COVID-19 that do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. The CHMP positive opinion is a scientific recommendation to the European Commission (EC), which authorises marketing approval in the European Union.

'We have accumulated the safety and efficacy data of regdanvimab in the treatment of patients infected with COVID-19 and its associated variant strains, including the more virulent Delta variant,' said Dr. HoUng Kim, Ph.D., Head of Medical and Marketing Division at Celltrion Healthcare. 'At Celltrion, we are proud to play our part in tackling the unprecedented global threat of COVID-19 and believe regdanvimab offers an important addition to the treatment arsenal. Using our stable supply system and commercial network, we will expedite required process and continue to work with stakeholders globally to ensure eligible patients can benefit from this treatment as quickly as possible. Currently, we are in discussions with regulatory agencies and companies from approximately 30 countries around the world, to supply our monoclonal antibody treatment for COVID-19 and those will be our top priorities in the coming months.'

The positive CHMP opinion was supported by data from the global Phase III clinical trial in which Celltrion enrolled more than 1,315 people to evaluate the efficacy and safety of regdanvimab in 13 countries including the U.S., Spain, and Romania. Data showed regdanvimab significantly reduced the risk of COVID-19 related hospitalisation or death by 72% for patients at high-risk of progressing to severe COVID-19.

'The primary benefits of monoclonal antibodies are their high specificity and safety - they are highly specific for a single target, so these monoclonal antibodies rarely cause undesirable side effects,' said Oana Sandulescu, MD, PhD, Associate Professor of Infectious Diseases at the Carol Davila University of Medicine and Pharmacy in Romania. 'An infusion of an hour of monoclonal antibodies like regdanvimab can ease COVID-19 symptoms and reduce complications in recently diagnosed, non-hospitalised people at high risk, and thus plays an important role in preventing further spread of the virus.'

Rolling review of regdanvimab had been initiated by the EMA on February this year and the announcement of the CHMP positive opinion for regdanvimab follows the submission of a marketing authorisation application (MAA) to the EMA seeking approval of regdanvimab in October 2021.

As of November 2021, more than 21,366 people have been treated with regdanvimab in 127 hospitals in the Republic of Korea.

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients' access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us.

About regdanvimab (CT-P59)

CT-P59 was identified as a potential treatment for COVID-19 through screening of antibody candidates and selecting those that showed the highest potency in neutralising the SARS-CoV-2 virus. In vitro and in vivo pre- clinical studies showed that CT-P59 strongly binds to SARS-CoV-2 RBD and significantly neutralise the wild type and mutant variants of concern. In in vivo models, CT-P59 effectively reduced the viral load of SARS-CoV-2 and inflammation in lung. Results from the global Phase I and Phase II/ III clinical trials of CT-P59 demonstrated a promising safety, tolerability, antiviral effect and efficacy profile in patients with mild-to-moderate symptoms of COVID-19.1 Celltrion also has recently commenced the development of a neutralising antibody cocktail with CT-P59 against new emerging variants of SARS-CoV-2.


Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion/Celltrion Healthcare that may constitute forward-looking statements, under pertinent securities laws.

These statements may be identified by words such as 'prepares', 'hopes to', 'upcoming', 'plans to', 'aims to', 'to be launched', 'is preparing, 'once gained', 'could', 'with the aim of', 'may', 'once identified', 'will', 'working towards', 'is due', 'become available', 'has potential to', the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion/Celltrion Healthcare's management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of Celltrion/Celltrion Healthcare believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion/Celltrion Healthcare undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.


19, Academy-ro



Incheon, Korea

Tel: +82-32-850-6400

T: +82-70-8228-2267~2268

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about CELLTRION, INC.
01/04Celltrion to Start Worldwide Trials of Inhalable COVID-19 Treatment; Shares Decline 3%
01/04South Korean Stocks Close Marginally Higher on Investors’ Wait-and-See Stance; LG..
01/04Celltrion's COVID-19 Treatment Drug Demonstrates Safety in Clinical Trial
2021U.S. OMICRON PLAN : boosters, free at-home tests, tighter travel rules
2021Celltrion signs COVID-19 antibody therapy supply deals with Europe
2021U.S. secures GSK-Vir COVID-19 antibody therapy doses worth $1 billion
2021Celltrion Receives CHMP Positive Opinion for regdanvimab (CT-P59) as One of the First M..
2021Celltrion Inc. Shares Rally After EU Approves Marketing of Its Covid-19 Treatment
2021European Commission Approves Celltrion's Antibody COVID-19 Treatment
2021Celltrion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Se..
More news
Analyst Recommendations on CELLTRION, INC.
More recommendations
Sales 2021 1 890 B 1,59 B 1,59 B
Net income 2021 577 B 0,49 B 0,49 B
Net cash 2021 271 B 0,23 B 0,23 B
P/E ratio 2021 39,1x
Yield 2021 0,01%
Capitalization 22 297 B 18 710 M 18 730 M
EV / Sales 2021 11,7x
EV / Sales 2022 9,81x
Nbr of Employees 2 034
Free-Float 74,0%
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 160 000,00 KRW
Average target price 266 271,71 KRW
Spread / Average Target 66,4%
EPS Revisions
Managers and Directors
Wu-Sung Ki Chief Executive Officer & Director
Ho-Seop Lee Finance Director
Jung-Jin Seo Chairman
Sung-Han Lee Head-Legal & Compliance Support
Dong-Il Kim Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CELLTRION, INC.-19.19%18 710
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%53 950
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068